Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial : The Lancet Oncology
Links shared publicly online about this topic.
- 227total visits
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial : The Lancet Oncology
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. By - Prof Sylvie Négrier MD, Gwe...
View full resource at thelancet.com
Tags: Cancer, Colorectal Cancer Medication, Renal Cell Carcinoma, Kidney Health, Urinary System, Phase 2 Clinical Trial, Avastin
Most Recently Shared on June 12, 2011 at 12:06 pm By:
Hurdles in combination therapy kidney cancer http://t.co/AUyycoE
Advertisement
